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Shahper N. Khan and Asad U. Khan*
Interdisciplinary Biotechnology Unit, Aligarh Muslim University, Aligarh, India
Multidrug-resistant (MDR) bacteria have become a severe threat to community
wellbeing. Conventional antibiotics are getting progressively more ineffective as a
consequence of resistance, making it imperative to realize improved antimicrobial
options. In this review we emphasized the microorganisms primarily reported of being
resistance, referred as ESKAPE pathogens (Enterococcus faecium, Staphylococcus
aureus, Klebsiella pneumoniae, Acinetobacter baumanii, Pseudomonas aeruginosa, and
Enterobacteriaceae) accentuating their capacity to “escape” from routine antimicrobial
regimes. The upcoming antimicrobial agents showing great potential and can serve as
alternative therapeutic options are discussed. We also provided succinct overview of
two evolving technologies; specifically network pharmacology and functional genomics
profiling. Furthermore, In vivo imaging techniques can provide novel targets and a real
time tool for potential lead molecule assessment. The employment of such approaches
at prelude of a drug development process, will enables more informed decisions on
candidate drug selection and will maximize or predict therapeutic potential before clinical
testing.
Keywords: multidrug-resistant, drug development, functional genomics, network pharmacology, in vivo imaging
INTRODUCTION
A change in the pattern of serious hospital infection after the introduction of antibiotics was
noticed early in the antibiotic era. Furthermore with the triumph of the penicillin discovery and
the synthesis of antibacterial sulfonamides in the initial half of the 20th century, the modern
antimicrobial revolution started. There onward, newer antimicrobial were reported and several
semi-synthetic and synthetic antibacterial agents came into existence. Antimicrobial drugs have
cured plenty of cases with life-threatening bacterial infections and relieved patients’ agony.
Unfortunately, unrestrained use of antibacterial past 50 years has wielded selection pressure on
susceptible bacteria stains, which attributed to the endurance of drug resistance (Levy and Marshall,
2004; Tacconelli, 2009), among them some are resistant to more than one antibiotic. Presently, the
treatment of these infections has once again becomes increasingly complicated as microorganisms
are becoming resistance to the available antimicrobial options (Pitout and Laupland, 2008;
Nordmann et al., 2011; Khan and Nordmann, 2012a; Labro and Bryskier, 2014). With course of
time, sustained selective pressure by various antibiotics has culminated into organisms augmenting
ancillary resistance mechanisms that led to multidrug resistance (MDR)—novel penicillin-binding
proteins (PBPs), enzyme dependant drug alteration, altered membrane permeability, mutated
drug targets and increased eﬄux pump expression. Further to mention few most challenging
MDR organisms presently being encountered includes the so called ESKAPE pathogens like
Pseudomonas aeruginosa, Acinetobacter baumannii, Escherichia coli, and Klebsiella neumoniae with
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extended-spectrum β-lactamases (ESBL), vancomycin resistant
enterococci (VRE), methicillin-resistant Staphylococcus aureus
(MRSA), vancomycin-resistant MRSA strains, extensively
drug-resistant (XDR) Mycobacterium tuberculosis and newly
identified transmissible carbapenamase, New Delhi metallo-beta-
lactamases (NDM) in Enterobacteriaceae (Alekshun and Levy,
2007; Gootz, 2010; Khan and Nordmann, 2012b). Carbapenems
were the only sensitive antibiotics for the treatment of MDR
coliforms but the development of carbapenem resistance recently
is a matter of great concern. Efforts directed toward identifying
newer antibiotics were formerly an exquisite research area
and development priority among pharmaceutical giants but
poor success rate has dampens the interest. Further studies
comprehending resistance illustrates that the evolution and
spread of antimicrobial resistance (AMR) is in fact, a very
convoluted issue. Hence, a sole target will not ensure eradication
of AMR; rather a coordinated multidisciplinary approach is
needed to tackle this problem (Smith et al., 2009; Cantas et al.,
2013). Mortality rates and length of hospital stay associated with
the treatment of drug resistant infections are about twice as big
when patients infected with drug sensitive bacteria of the same
species, thereby ensuing inflation in healthcare costs.
The aim of this article is to emphasize the ever growing
problem of antimicrobial resistance, counting in the present
approaches to limit the spread of MDR. We specifically
highlighted how the emerging technologies could be a great
promise for new antimicrobial discovery.
FAILURE OF PRESENT MEASURES TO
COMBAT MDR
Multidrug-resistant is prevalent in nature, and the strategy of
eliminating resistance genes makes no sense, as the natural
function of most resistance genes is not primarily confirming
MDR (Morar and Wright, 2010). Most probably, there is a huge
“intrinsic resistome” in bacterial organisms, composed of various
genes with diverse phylogeny which contribute to resistance only
on interaction with the antibiotic (Fajardo et al., 2008; Girgis
et al., 2009; Sommer et al., 2009). Possible strategy to combat
with emerging drug resistance is to control the emergence,
selection, and spread of MDR strains of bacteria from hospital
settings and community (Wright, 2009). The conventional
strategies of combating the emergence and spread of MDR
atypically relies on the discovery of newer drugs (Wright, 2009;
Nordmann et al., 2012), reduction in antibiotic induced bacterial
mutation, genetics dependant recombination and horizontal-
transfer at lower concentration of drugs (Couce and Blázquez,
2009), suppression of phenotypic traits of resistance (Udekwu
et al., 2009), use of combinations therapy (De Cristóbal et al.,
2008), including antagonistic drugs (Drew, 2009), early intensive
(frontline) therapy, maintaining a low bacterial density (Motter,
2010), and lately, surveillance of hypermutable organisms
(Oliver et al., 2000; Carattoli, 2009) and targeting regulating
functions necessary for infection (Dandekar and Dandekar, 2010;
Greenberg et al., 2010). In essence, these preventive measures are
proving increasingly inadequate in the existing global scenario
of MDR (Boucher et al., 2009). Averting the spread of resistance
can apparently be significant for the person, but exhibits weak
impact on the community (Durante-Mangoni and Zarrilli,
2011). Procedures that might work in the initial phase of the
development of resistance in hospitals or nations with low
rates of MDR, may not be competent enough in regions with
prevailing higher resistance frequency (De Gelder et al., 2007).
Reports from regions with low levels of MDR such as Sweden,
revealed that discontinuance of trimethoprim use for 2 years had
no impact on the resistance rate of Escherichia coli. That was
further linked to the extensive dissemination of trimethoprim
resistance genes (dfr) along with other resistance determinants,
thus encouraging co-selection of dfr with other resistance genes
as well (Brolund et al., 2010). In a global scenario, eventually,
resistance commencing in these heavily contaminated “sources
of resistance” will infest areas that are still cleaner (Thaller
et al., 2010). Thus, antibiotic resistance keep evolving to attain
higher antibiotic resistance exhibiting elevated bacterial genetic
evolvability, a phenomenon known as “genetic capitalism”, where
the rich tends to become richer. It refers to further adaptive
potential of an organism to enrich their resistance mechanism
either via mutational or gene acquisition events.
POTENTIAL THERAPEUTIC
INTERVENTIONS
Molecules Targeting Protein Synthesis
Among the many exploited targets the one, which has been
frequently approved by nature and by many successful clinical
trial is the ribosome. Many antibiotics targeting protein synthesis
are in development or in different phases of clinical trials as a
prospective remedy of temperate-to-serious community acquired
bacterial infections: solithromycin, cethromycin, omadacycline,
CEM-102, GSK1322322, radezolid, and tedizolid. Interestingly,
antibiotics targeting the cellular protein synthesis, TP-434,
GSK2251052, and plazomicin, are reported to have a range
that covers drug resistant gram negative class of bacteria.
Among which, TP-434 (Figure 1) is a C7, C9 di-substituted
broad-spectrum tetracycline based antibiotic was discovered and
being developed by Tetraphase Pharmaceuticals, MA, showed
effective mechanism-driven impediment of protein synthesis in a
coupled transcription/translation assay [half maximal inhibitory
concentration (IC50) = 0.29 µg/mL] and a competition assay
employing radio labeled tetracycline (Grossman et al., 2012).
Furthermore, TP-434 activity is also reported against tetracycline-
specific eﬄux proteins (including mepA) genes bearing stains,
ribosomal defense mechanisms and for enzymes capable of
destructing tetracycline antibiotics (Sutcliffe et al., 2013). Further,
TP-434 is insusceptible to blaNDM−1 positive carbapenemase
that has recently been reported in enterobacteriaceae. Plazomicin
(ACHN-490, Figure 1), a “neoglycoside,” a semisynthetic drug
evolved from sisomicin with considerably enhanced efficacy
toward amikacin and gentamicin resistant bacteria (Aggen et al.,
2010; Armstrong and Miller, 2010). The minimum inhibitory
concentration (MIC) 50/90 reported for plazomicin ranges in 0.5–
1 µg/mL against resistant K. pneumoniae, including the serine
Frontiers in Microbiology | www.frontiersin.org 2 February 2016 | Volume 7 | Article 174
fmicb-07-00174 February 16, 2016 Time: 16:27 # 3
Khan and Khan Combating Multidrug Resistance
FIGURE 1 | Chemical structure of protein synthesis inhibitors as
promising antimicrobial agents.
carbapenemase KPC strains and 1/2 µg/mL against 493 strains
of MRSA positive bacteria (Tenover et al., 2011). Whereas, MICs
tested against 65 carbapenem resistant enterobacteriaceae was
found to be ≤2 µg/mL except for NDM metallo-β-lactamase
producers (Livermore et al., 2011). Plazomicin has successfully
concluded a level 2 in global multilocation indiscriminate double
blind trial evaluating its efficacy relative to levofloxacin, a
gold standard for complex urinary tract infection (cUTI) and
acute pyelonephritis (AP) and now registered in a level 3 trial
stage (ClinicalTrials.gov identifier: NCT01970371). GSK2251052
(Figure 1), is a novel boron derivative that interacts with
the leucyl-tRNA synthetase at adenosine ribose (A76) termini
with an IC50 of 0.31 µM, thereby aborting protein synthesis
(Goldstein et al., 2013). The compound has shown variable range
of MIC50/90 for various rampant gram negative aerobic and
anaerobic bacteria and anaerobic gram-positive strains (Mendes
et al., 2013). Further, in an in vitro potency test against blaNDM−1
producing enterobacteriaceae isolates, MIC90 of the compound
was reported to be 1 µg/mL, with a range of 0.5–2 µg/mL. This
novel antibiotic has also shown is activity toward category A
and B bacterial biothreat infections, with MIC90 concentration
in the rage of 0.12–2 µg/ml (Heine et al., 2011). When tested
on healthy cohort as single IV doses of 200, 400, 900, 2,000,
or 3,000 mg (1-hour infusion) and as multiple ascending doses
(MADs) of 500, 750, 1,200, or 2,000 mg two times a day for
8 days (500 mg) or 14 days (all other cohorts) was well taken,
with no severe implications leading to patients withdrawal but a
recent article reports development of some resistance toward it
due to specific mutations in the LeuRS editing domain (O’Dwyer
et al., 2015). A review by Sutcliffe on antibiotics targeting protein
synthesis describes them in detail (Sutcliffe, 2011). Specifically,
Dewan et al. (2014) describes in detail the importance aminoacyl-
tRNA synthetases as a therapeutic target for novel antibiotic
development.
Peptides
Combinational administration of antimicrobial peptides (AMP’s)
with other antimicrobials has been recommended as an
alternative strategy for enhanced therapeutic outcomes. They act
by affecting cell membrane integrity, inhibiting protein and cell
wall synthesis, altering enzyme activity, and others (Guilhelmelli
et al., 2013). Their discrete therapeutic potency and less side
effects makes AMP’s interesting candidates for concurrent or
subsequent use in diverse bacterial infections. AMP’s are recently
regarded as a viable option for eradicating the multidrug resistant
micro-organisms, based on their distinct mechanism of action
than that of the presently used antibiotics (Fjell et al., 2011;
Nan et al., 2012). Till date, more than 3700 AMP’s have already
been reported and characterized from flora, faunna, and other
sources (Tossi and Sandri, 2002). AMP’s can also be produced
synthetically and moreover, recombinant AMP’s can be yielded
by various recombinant cell and/or organisms (Yu et al., 2010).
A good number of synthetic AMPs are being tested in clinical
trials and in excess of 15 peptides or mimetics are in (or have
completed) clinical testing as antimicrobial agents. In a phase
1/2 of clinical testing, the AMP hLF1–11 (1–11 amino acids long
amino-terminal of human lactoferrin) was found to be risk free
with no after effects when delivered intravenously (Velden et al.,
2009). Two peptides, pexignan and omiganan have exhibited
efficacy in Phase III clinical trials but waiting for approval.
Pexiganan (Lipsky et al., 2008), a derived from magainin,
demonstrated similar effectiveness to an oral fluoroquinolone for
treating patients with diabetes foot ulcer but was not approved
by the US Food and Drug Administration, although there is
indication that it might resurface in clinical trials. Omiganan
(MBI226), a derivative of indolicidin, proved competent in
drastically limiting catheter colonization and microbial tunnel
infections during catheterization (ClinicalTrials.gov identifier:
NCT00608959). AMP’s when tested for treating UTI, the most
common infections in hospital settings and well documented
in general population, seems to work best due to the optimum
environment where peptides naturally, exhibit their potency
(Lupetti et al., 2003; Melendez-Alafort et al., 2004). Cudic et al.
(2003), illustrated that higher salt concentrations decreases the
antimicrobial activity of various AMP’s, however, lactoferricins
and derivates thereof, are quite active against UTI, regardless
of limited antimicrobial activity at higher salt concentration as
suggested in in vitro settings. Probably, the peptide is effective in
eradicating urinary tract infections at remote sites, likely through
passive or active transfer of the peptide to the contagion site via
renal discharge (Del Olmo et al., 2009; Fornili et al., 2010).
Administration of antimicrobial peptides treated equipment
offers potential microbial protection, although the attrition in
antimicrobial attributes due to cross linking of the peptide to
solid supports must be addressed (Onaizi and Leong, 2011).
There are satisfying instances for cationic peptides possessing
clinical efficacy (Gordon et al., 2005); polymyxin a cationic
lipopeptide is the last resort treatment for multi-drug resistant
Pseudomonas and Acinetobacter infections, the gramicidin S a
cyclic cationic peptide is frequently prescribed in topical and
eye infections, and the cationic nisin antibiotic is already an
approved food supplement in Europe. As per our inference,
the increasing accessibility and exploitation of high throughput
involved strategies has shown substantial prospects to improve
the search for the next generation therapeutic peptides and
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peptide mimetic as antimicrobials not only specific for bacteria
that are resistant to existing antibiotics but also for eliminating
other disease causing bugs like protozoa, helminthes, insects and
fungi (Bommarius and Kalman, 2009; Tavares et al., 2013).
Vaccines
Rational designing of vaccines have markedly improved with the
advancement of recombinant DNA technology against complex
human pathologies. In spite of extraordinary performances in
pre-clinical and clinical testing, only few recombinant vaccines
are deemed safe for humans use till date. Wherein, extensive
screening procedures for its production and speculations about
their use might be accountable. Recent application of new
approaches like systems biology and advanced immunology
to better understand mechanism of vaccines is propelling the
evolution of vaccinology. Moreover, the outcomes of synthetic
biology in vaccine design as evident in the first synthetic
bacterium, demonstrates its distinction and rational attributes.
Over the last few years there have been several excellent
research articles describing strategies of creating the ‘optimal’
vaccine, as well as highlighting the significant challenges
of developing an effective vaccines (Otto, 2010; Wu et al.,
2012). Inactivated bacterial strains have shown to be extremely
immunogenic against Gram-negative bacteria and exhibit
protective immunity against several other bacterial infections.
However, its applicability in human is limited due to the presence
of lipopolysaccharide induced endotoxin levels. Nevertheless, in
a recent report it was suggested that lipopolysaccharide impaired
and inactivated A. baumannii whole cells can induce protection
against A. baumannii infections. In which, the endotoxins levels
were found to be reduced (<1.0 toxin unit/106 cells) relative to
the wild type strain, as on inactivation of lipopolysaccharide due
to a mutation in the lpxD gene (García-Quintanilla et al., 2014).
Vaccines, intended at combat P. aeruginosa infections in cystic
fibrosis have been developed and are under different clinical
phases, though none has been recommended for use (Johansen
and Gøtzsche, 2015). Besides the ongoing improvement in whole-
cell enterotoxigenic Escherichia coli (ETEC) vaccine development
the research on subunit or polypeptide vaccines, offers great
therapeutic promise. Recent article by Zhang and Sack (2015), has
critically summarizes the progress in the development of ETEC
vaccine.
Despite the daunting odds of success, there are at least
seven active vaccine efforts are ongoing in different stages of
clinical development (GlaxoSmithKline/Nabi, Pfizer/Inhibitex,
Sanofi Pasteur/Syntiron, Novartis, Novadigm, Integrated
Biotherapeutics, and Vaccine Research International). Several
studies have been conducted to evaluate the potential of
vaccination with microbial surface components illustrating
adhesive matrix molecules (MSCRAMMs) whole protein
or subunit offers superior protection against staphylococcal
infection. Earlier reported, recombinant parts of collagen
adhesin (CNA) were shown to provide immunity in a murine
model of sepsis (Kuklin et al., 2006). Shkreta et al. (2004)
illustrated the protective potential of both clumping factor A
(ClfA) and Fibronectin binding protein (FnBP) as an optimal
vaccination strategy in bovine mastitis model, eliciting cellular
and humoral immune response providing partial protection
against Staphylococcal mastitis. Recently in an In silico analysis,
potential multisubunit vaccine targets like ClfA, ron-regulated
surface determinant (IsdB) and gamma hemolysin (Hlg) were
predicted against S. aureus (Delfani et al., 2015). Likewise, several
extracellular and surface protein factors in combination with
aluminum hydroxide have shown to induce high and broad
protection against S. aureus (Bagnoli et al., 2015).
Another promising alternative to vaccine prophylaxis against
bacterial pathogenesis is the ‘DNA-vaccine’, wherein DNA
sequence encodes the antigen(s) against which an immune
response is sought. It will be less labor intensive and may offer
a unique method for vaccination (Tang et al., 1992). Though to
obtain an improved immunogenic response of DNA vaccines
entails detailed familiarity of underlying mechanism through
which DNA vaccines provide immunity to the patient and
needs the right combination adjuvants as crucial molecules for
strengthening the response (Coban et al., 2008). In implant
infections caused by S. aureus, MSCRAMM is reported to act
as an excellent immunogen for an anti-Staphylococcus vaccine.
A survey comprising multiple studies in where MSCRAMMs
of staphylococcal are exploited as the immunogenic entity,
which can implemented following the start of infection as
presented in a recent review by Arciola et al., where the
authors suggests a “Decalogue” for a rational selection of
specific target in constructing DNA vaccines to impede infections
in implants (Arciola et al., 2009). Another proposed strategy
to induce protective immunity against infectious diseases is
the application of live attenuated vaccines. Recent studes
illustrates that nasopharyngeal colonization with Streptococcus
pneumoniae induces protective immunity against subsequent
invasive infection, suggesting live vaccination through attenuated
bacteria could be a treatment of choice in future. However
the bacterial attributes influencing the strength of this adaptive
immune response are still to be explored (Cohen et al., 2012).
THE SEARCH OF NOVEL
ANTIMICROBIALS
Concept of Network Pharmacology
The conception of directed “magic bullets” has long been a
therapeutic goal to achieve since Paul Ehrlich (Strebhardt and
Ullrich, 2008) and a realistic standard in drug development for
past three decades. The central concept of drug development is
the notion of developing maximally selective molecules directed
to discrete drug targets. Conversely, current therapeutics affects
multiple proteins rather than discrete target to execute its effect.
Development in the area of systems biology further indicates
phenotypic robustness and a network structure implying that
specific ligands, compared to multi-target ones, exhibit inferior
to expected clinical potency. This revised paradigm about
polypharmacology offers improved strategy to rise upon the
major pitfalls in new antibiotic development, i.e., efficacy and
toxicity. Combining system biology with polypharmacology
brings in the opportunity of increasing the existing druggable
targets. Nevertheless, the coherent design of polypharmacology
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needs to fulfill the requirement for new procedures to confirm
target associations and augment structure-activity interactions
while preserving drug like attributes. Progresses in similar
avenues are paying the path toward the next paradigm in novel
antibiotic discovery as ‘network pharmacology’.
The notion about ‘one drug for one target’ has affected various
facets of drug development approach, like disease categorization,
target validation, drug design, and planning of clinical testing.
Though, a growing data in post-genomics research is suggesting
a more complicated scenario in drug action. An interesting
research by Yildirim et al. (2007), illustrates not only the existence
of several keys for each lock but also a single key for multiple
locks. Employing network analysis of combined profiles and
a network distance metric, can differentiate between soothing
drugs, which ease symptoms, and drugs affecting directly the
concern disease genes. Furthermore, the trends in recent years
toward the drugs that target the genes associated with disease
were emphasized by the network distance metric. It has been
well accepted that many effective drugs in therapeutic areas as
varied as oncology, psychiatry and antimicrobials affects multiple
rather than single targets (Paolini et al., 2006; Tian and Liu,
2012). Many efficient antibiotics are directed toward multiple
proteins concurrently rather than individual protein (Lange et al.,
2007). For instance, the antimicrobial property of beta-lactams
is reliant on the inhibition of more than one PBPs. Indeed, as
multiple PBPs can be eliminated with least effect on phenotype
(Denome et al., 1999), the approach of lone target essentiality may
not have revealed this significant group of antimicrobial drug
targets. Likewise, fluoroquinolone based antibiotics can inhibit
more than one target proteins ParC and GyrA (Janoir et al.,
1996). D-Cycloserine is reported to inhibit four proteins, dimer of
alanine racemases and D-Ala-D-Ala ligases. Similarly, fosfomycin
circumvent the excess of UDP N-acetylglucosamine enolpyruvyl
transferases by restraining them both. Consequently, any effort
in the direction of drug designing for combating drug resistance,
could consider the development of procedures to identify and
evaluate which group of targets can be repressed by one single
drug and are indispensible, either alone (‘dualessentials’) or when
taken together (‘synthetic lethals’).
Network biology is suggested to play imperative role in
drug target characterization. Is it feasible to recognize drug
targets by tracing their location in a biological network? When
the researchers mapped drug targets against human protein
interaction data, result suggests that drug targets tend to have
more interactions than average proteins but fewer interactions
than crucial proteins to a statistically significant degree (Hopkins,
2007, 2008). The findings about the linkage among drug targets
that are not exclusively essential, opens up the avenues for
statistical analysis to serve as a vital tool for scoring them.
Conventionally, medicinal chemists considered the design of
ligands with multiple activities with apprehension, skeptical
about conjugated ligands with high molecular weights complex
and/or their structure-activity relationships (Hopkins et al.,
2006; Morphy and Rankovic, 2006). Though, polypharmacology
of standard drugs illustrates that a more opportunistic plan
exploring multi-target action could be more efficient. Employing
chemogenomics along with network biology will bring in a
efficient network-pharmacology approach to drug design (Keiser
et al., 2007; Morphy and Rankovic, 2007). Developing strategy
to assist polypharmacology will further help to predict better
efficacy and redundant off-target properties.
Functional Genomics in Drug Designing
The tremendous advancement in the technology for genome
screening had a substantial impact on all biological sciences,
including antimicrobial research. Since the decoding of the
Haemophilus influenza genome (Fleischmann et al., 1995),
various other bacterial genomes were deduced. Complete
genomes of >180 bacteria were sequenced and are now
freely accessible, including various imperative disease causing
pathogens (e.g., http://www.genomenewsnetwork.org/resources/
sequenced_genomes/genome_guide_p1.shtml). Therefore, the
drug development industry exploited the sequencing data as
the basis for a rational, target-specific novel drug designing
approach to complement the conventional strategy. Central to
the paradigm shift was the idea of the occurrence of the so-
far unexploited targets with the prospective for effective and
discerning antibiotics for broad spectrum of bacterial infections
(McDevitt et al., 2002; Gwynn et al., 2010; Brunschweiger and
Hall, 2012). An array of genomics platforms are employed
in the present antiinfectious drug development process to
lay more proficient procedure compared to conventional
strategy. Herein, we proposed a more robust strategy as an
alternative for the discovery of next generation antibiotics
(Figure 2), which includes all possible coverage for better
output. Including knockout analyses and mutation studies in
the strategy will enhance the prioritization and validation of
prospective novel drug target by questioning its importance
for bacterial existence. Applications of genetically manipulated
cell, along with holistic profiling strategies like ‘OMICS,’ i.e.,
transcriptomic and proteomic are contributory in verifying the
mode of action (MOA) while screening lead molecules from
target assays. Functional genomics strategies also offers vital
clues on the mechanism of lead molecules screened through the
empiric approach for novel antibacterial discovery. Furthermore,
comparing genomes facilitates the identification of proteins that
are conserved across the clinically critical pathogens, assisting
functional characterization of new genes and identification of
novel targets. Genome wide gene silencing studies facilitate an
approximation of the number of genes necessary for survival
of various bacterial species. The inference on the role of
same gene product essentiality (‘ortholog’) in different species
will augment the feasibility of such targets. While selecting a
target diverse criterion, such as screening competence, drug like
attributes and metabolical context are of a great significance.
Although, data on these features are often not accessible and
even some targets are not completely characterized. The number
of uncharacterized targets typically increases when focusing on
attributes preserved in a selective group of pathogens (narrowed
range of bacteria). Growth studies with different supplements,
cytological assessment, transcriptome, proteome analyses, and
metabolic labeling experiments of conditional mutants may assist
in the evaluation of corresponding functional genes. Further
interesting strategy to explore novel drug is to evaluate the
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FIGURE 2 | Alternative approach for the discovery of next generation antibiotics.
molecular action of bacteriophages to arrest critical cellular
pathways. As done by Liu et al. (2004), on sequencing 26
S. aureus phages thirty one (31) novel polypeptide were identified
that on expression exhibit cell death in S. aureus. Affinity
chromatography illustrates the role of DnaI as a target protein,
a requisite protein for primosome activity on the initiation
of DNA replication. Such screening techniques can be further
extended to other species as well and could be instrumental
in proving imperative information and as screening tools for
novel or unexplored targets. In addition functional genomics
applications have proved to be indispensable for expediting the
characterization of mechanism of action for novel compounds
with antinfectious activity and offers novel mechanism based
screening options by generating and characterizing point
mutations that confers drug resistance. In general conditional
mutants with target gene repression illustrate an increase in
sensitivity toward that target specific inhibitor. When analyzed,
the relative growth suppression of these mutants to the wild type
enables an easy validation confirming the mechanism of novel
drugs/hits, as reported by DeVito et al. (2002) and Forsyth et al.
(2002).
An approach of global expression profiling can revolutionize
the analysis of drug targets holistically as never before. As whole
genome profiling offers the static blueprint of cells attributes, as
being highly dynamic in nature the transcriptome and proteome
are appropriate to obtain snapshots of that cell physiology
when challenged by environmental alterations, exposure to
stress or antibiotic administration. As application of a DNA
microarray provides direct assessment of the mRNA of the gene
of interest, the proteomic profiling by 2D gel electrophoresis
involves an implicit protein atlas needed initially to confirm the
identity of each protein (as determined by mass spectrometry)
to its spot location on the 2D gel (Brötz-Oesterhelt et al.,
2005). The expression profiles resulted from these techniques
illustrates the molecular insight of the adaptive physiology of
bacteria like the regulatory mechanism, signal transduction
and the underlying metabolism that influence the phenotypic
outcomes. Transcriptome as well as proteome profiling were
widely used to study the physiology of bacteria in response
to various environmental stresses provided particularly useful
information about the underlying network of adaptive responses.
As a proof-of-concept is the B. subtilis mutant down regulating
the peptide deformylase, wherein the proteomic profiling of
this strain matched adequately well with the wild-type strain
exposed to the deformylase inhibitor actinonin (Bandow et al.,
2003). Furthermore, bacterial acetyl-CoA carboxylase (ACC) is
recently been suggested as the target of moiramide B based on a
reference compilation of transcriptome profiles (Freiberg et al.,
2004, 2005). In a recent interesting work Murray et al. (2015)
has employed expression- and fitness-based genomic strategies
to validate role of genetic loci exhibiting drug resistance in
human pathogen P. aeruginosa. Signifying that gene expression
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standalone is not a reliable predictor of resistance determinants.
Moreover when combine together, whole genome expression and
fitness correlation may offer better mechanistic perceptions about
multidrug resistance.
In Vivo Imaging Technologies
Recently, in vivo imaging techniques are being proved to be
a powerful complement to various platforms of antimicrobial
resistance and drug discovery (Probst et al., 2012; Roda
and Guardigli, 2012). It may not only minimize the use of
histopathological examination of autopsies but also be helpful
in limiting the animal sacrifice and cost for in vivo drug-
kinetic studies. Hence, we propose that improvement of intravital
dynamic monitoring strategies to probe cellular phenotypes
will reflect as wise drug development investment. Real time
monitoring enables a faster readout of drug action in the
complex model organisms, thus facilitating comprehensive
assessment of drug profiling in vivo. Moreover, this could
enable lead optimization and medicinal chemistry can be
directed by instructive functional in vivo response data. The
clinical reliability of highthroughput screens and in vivo
monitoring strategies are yet to be fully comprehended. In
particular, the progress in bioluminescence based monitoring
of disease progression in vivo is ever increasing. Further
identifies underlying physiology, such as signal transduction,
proliferation and cell renewal to be examined in the purview
of an intact organism. Two commonly employed strategies
for incorporating bioluminescent marker in a model organism
are: First is the lux operon from Photorhabdus luminescens or
Xenorhabdus luminescens, encodes genes to produce luciferase
and its substrate luciferin constitutively, and glow even absence of
any exogenous substrate. The lux operon gets stably incorporated
to other bacterial species but fail to integrate in higher species,
though continuous efforts are make to use it as a reporter
in mammalian system. The second strategy for bioluminescent
probes uses enzyme luciferase from firefly (Photinus pyralis) or
sea pansy (Renilla reniliformis), as firefly and Renilla luciferase
require two distinct substrates, which make it possible to
link them with two different biological processes in the same
research model (Bhaumik and Gambhir, 2002; Ng et al., 2011).
However, each reporter differs in the pharmacokinetic of their
substrate, as on intraperitoneal administration of luciferin, firefly
luciferase bioluminescence attain saturation in about 5–10 min
and stays almost constant for 30 min (Paroo et al., 2004),
however, renilla luciferase reach to its maxima in 1 min on
intravenous coelenterazine administration and declines back in
10 min (Bhaumik and Gambhir, 2002). This technology can be
successfully employed to study a variety of infection and their
progression in animal models (Figure 3). Also manifested by
the work of other researchers, that bioluminescence imaging can
be used to validate new features in host–pathogen interactions.
Furthermore developments in the live cell-fluorescent reporter
molecules, brings in the opportunity to adopt in vivo monitoring
applications in drug development (Carragher et al., 2012).
Past few years, array of nanoparticles have emerged with
a promise of superior atttributes for in vivo fluorescence
imaging technology. Besides providing dynamic size range, these
particles offers diverse structural and optical properties with
superior signals strength compared to organic fluorophores,
providing more sensitive visualization of even sparse biomarkers.
Furthermore, nanoparticles can incorporate multiple probes
due larger surface area, facilitating multivalent targeting. Above
mentioned attributes make these nanocarriers fit for therapeutic
applications, biomedical imaging or a combination of both
(theranostics). Quantum dots (QDs) are the best characterized
and most studied nanocrystals (Mandal and Parvin, 2011; Li et al.,
2012). These minute nanomaterials are semiconductive in nature
and have an adjustable emission fluorescence that can be adjusted
by regulating their synthesis (Bentolila et al., 2009). Furthermore
can be visualized in a wide, from the ultraviolet to the near
infrared exhibit higher intensity and photoresistant attributes.
Recently, QDs treated with coordination complexes were used to
specifically visualize a rough Escherichia coli mutant facilitating
optical detection in murine infection model (Leevy et al., 2008).
Various other nanoparticles that have been developed for in vivo
fluorescence imaging applications are metallic, hybrid, C dots,
polymeric or biodegradable in nature (Coto-García et al., 2011).
Recent development in capturing detailed images and image
based analysis softwares are beginning to impact the design of
algorithms that can be customized to fit intricate and pertinent
biological models and tissue specimen (Jones et al., 2009).
Amendable image analyzing software’s can leverage quantitative
data from complex biological systems, integrating varied cell
types, fresh biopsies, or material from cell lines or primary cells
for efficient mimicking of the cellular environment. Therefore,
high-resolution in vivo imaging should facilitate drug discovery
per se and understanding of the drug therapeutic effectiveness
(Table 1), and will apparently increase the success rate in clinical
testing by providing pertinent biological perspective to genomic
and proteomic approaches.
CONCLUSION AND FUTURE
PERSPECTIVE
The yin and yang of novel antibiotic discovery swings around
from a serious need for antibiotics to eradicate drug resistant
bacteria to antimicrobial agents. Ever increasing resistance
despite the rigorous attempts for control use of antibiotics
and sanitize hospitals routinely is the driver for the need
of next generation antibiotics. These bacteria “superbugs”
have escaped the clinical settings and attain the status
of community acquired pathogens. Besides the upcoming
promising antiinfective agents as discussed in this article earlier,
there is the need to adopt alternative approaches for the discovery
of next generation of antibiotics. The strategies discussed
in this review are network pharmacology and functional
genomics in complement with in vivo imaging platforms.
The network pharmacology encompasses systems biology,
network analysis, connectivity, redundancy, and pleiotropy to
improve clinical efficacy and understanding side effects and
toxicity. Functional genomics techniques are proved to be
indispensible for in vitro target authentication and elucidating
mechanism of action of novel antibacterial. In addition, the
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FIGURE 3 | Scheme representing the usage of in vivo imaging technique for the assessment of bacterial infection in murine model. The bacterial cells
bearing plasmid with reporter genes expressed will provide luminescence signals when injected with appropriate substrate provides real time readout for the extent
of infection and/or therapeutic efficacy.
TABLE 1 | Potential applications of in vivo imaging in drug discovery.
Assessment of disease model efficiency Disease model can be assessed for the optimal engraftment or infection from orthotropic cells
before treatment regimes
Potential hit screening Evaluation of MIC values across multiple pathways to determine the response of target activity
Biomarker discovery Detection of post-translational markers of therapeutic relevance from clinical biopsy or body fluids
Identify drug–target mechanisms Identification and validation of drug combination strategies and synergism of drugs
Predictive in vivo pharmacodynamics Monitor organ-specific response and correlate with functional drug response
Drug candidate profiling in vitro Establish broad pathway-activity mechanisms
Confirming functional genomics screens and pathways Characterize impact of knockdown of genes on key pathways
approach of functional genomics not only relies on target-
based screening but also supports the traditional screening
strategy by predicting novel mechanism for hits and natural
products with potential antibacterial activity and unknown
targets. Complementary to approach of drug discovery, in vivo
imaging is an economical, user friendly and radioactive free
tool that can extract quick semi-qualitative or quantitative
information representing physiological milieu from the cellular
to the computable form. Key for best realization of imaging and
post-translational pathway modeling approaches into routine
antibiotic discovery relies on its early integration with target
specific drug development efforts. Validating efficiency and
safety profiles of hit molecules in pathological models, before
cost intensive medicinal approaches, offer a perfect solution
for reducing the unsustainable expense. In summary, there is
strong likelihood that the combination of both the traditional
and genomics-based approaches, together with the live cell
visualization techniques, will led to better strategies for the
discovery of newer antibiotics to combat the emergence of
bacterial resistance.
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